CRAI vs GILD · P/E 20, rev $411.8M vs P/E 18, rev $7.80B
CRA International Inc (CRAI) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
CRA International Inc (CRAI) is a consulting services company listed on NASDAQ.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported CRAI revenue for 2026-07-04 was $411.8M. Net income was $24.6M. CRAI currently screens at market cap $952.1M and trailing P/E 20.4.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
CRAI currently screens at market cap $952.1M and trailing P/E 20.4. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the CRAI and GILD stock pages for the full models.
Not investment advice.